Latest Clinical Understanding from VERTIS CV for Patients with Diabetes, Cardiovascular and Renal Disease: A Cross-Specialty Discussion

Chairs: Chris Cannon (USA), Sam Dagogo-Jack (USA)
Faculty: David Cherney (CAN), Ildiko Lingvay (USA), Francesco Cosentino (SWE)

14:30 – 14:35Opening RemarksChairs (USA)
14:35 – 14:45Ertugliflozin and VERTIS CV – New Data Expanding Our Understanding for the Treatment of Patients With Type 2 Diabetes and Cardiovascular DiseaseSam Dagogo-Jack (USA)
14:45 – 14:55Recent Data on the Efficacy and Safety of Ertugliflozin Using Insulin in Patients with Type 2 Diabetes Mellitus and Established Cardiovascular DiseaseIldiko Lingvay (USA)
14:55 – 15:05The Latest VERTIS CV Heart Failure Results – Adding to Our Clinical Understanding From a Cardiologist’s ViewFrancesco Cosentino (SWE)
15:05 – 15:15New VERTIS CV Kidney Protection Results – Adding to Our Clinical  Understanding From a Nephrologist’s ViewDavid Cherney (CAN)
15:15 – 15:28What Does It All Mean For Our Patients? A Cross-Specialty Faculty Roundtable DiscussionFaculty
15:28 – 15:30Closing RemarksChairs (USA)